<DOC>
	<DOCNO>NCT00079430</DOCNO>
	<brief_summary>This phase I trial study side effect best dose adjuvant intraperitoneal carboplatin give together paclitaxel bevacizumab treat patient undergone debulking surgery stage II , stage III , stage IV ovarian epithelial , primary peritoneal , fallopian tube cancer . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop tumor cell divide stop grow die . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . It yet know whether carboplatin , paclitaxel , bevacizumab effective carboplatin paclitaxel treat ovarian epithelial primary peritoneal cancer , fallopian tube cancer .</brief_summary>
	<brief_title>Paclitaxel , Bevacizumab And Adjuvant Intraperitoneal Carboplatin Treating Patients Who Had Initial Debulking Surgery Stage II , Stage III , Stage IV Ovarian Epithelial , Primary Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose intraperitoneal carboplatin administer paclitaxel course 1 , patient stage II-IV ovarian epithelial , primary peritoneal , fallopian tube cancer initial debulking surgery . II . Determine feasibility regimen patient . III . Determine feasibility add IV bevacizumab regimen course 2-6 . SECONDARY OBJECTIVES : I . Determine toxicity profile regimen patient . II . Determine toxicity profile paclitaxel bevacizumab IV combination intraperitoneal carboplatin patient . III . Determine response rate ( patient measurable disease expand cohort ) progression-free survival patient treat regimen . OUTLINE : This multicenter , dose-escalation study intraperitoneal carboplatin . Patients receive paclitaxel IV 3 hour follow intraperitoneal carboplatin 15 minute day 1 course 1 . Beginning course 2 , patient also receive bevacizumab IV 30-90 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos carboplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional 20-40 patient treat dose level . Patients follow every 3 month 1 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Endometrioid</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Brenner Tumor</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Cystadenocarcinoma , Mucinous</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm ovarian epithelial , primary peritoneal , fallopian tube cancer Stage IIIV disease The following histologic epithelial cell type eligible : Serous adenocarcinoma Mucinous adenocarcinoma Clear cell adenocarcinoma Transitional cell carcinoma Adenocarcinoma otherwise specify Endometrioid adenocarcinoma Undifferentiated carcinoma Mixed epithelial carcinoma Malignant Brenner 's tumor Optimal ( ≤ 1 cm residual disease ) OR suboptimal residual disease initial debulking surgery ( perform within past 12 week ) Synchronous primary endometrial cancer OR prior history endometrial cancer allow provide follow true : Stage IB disease less Less 3 mm invasion without vascular lymphatic invasion No poorly differentiate subtypes , include follow : Papillary serous Clear cell Other FIGO grade 3 lesion No epithelial tumor low malignant potential ( borderline tumor ) No CNS disease , include primary brain tumor , seizures control standard medical therapy , brain metastasis history evidence upon physical examination within past 6 month Performance status GOG 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 INR ≤ 1.5 PTT &lt; 1.2 time upper limit normal ( ULN ) No active bleed pathologic condition carry high risk bleeding ( e.g. , know bleed disorder , coagulopathy , tumor involve major vessel ) AST ≤ 3 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3 time ULN Bilirubin ≤ 1.5 time ULN No acute hepatitis Creatinine ≤ 2.0 mg/dL Urine proteincreatinine ratio &lt; 1.0 OR protein 1.0 g 24 hour urine collection Cardiac conduction abnormality ( e.g. , bundle branch block heart block ) allow provided patient 's cardiac status stable ≥ 6 month study entry No clinically significant cardiovascular disease , include follow : Uncontrolled hypertension , define systolic BP &gt; 150 mm Hg diastolic BP &gt; 90 mm Hg Myocardial infarction unstable angina within past 6 month New York Heart Association class IIIV congestive heart failure Serious cardiac arrhythmia require medication Peripheral vascular disease ≥ CTCAE grade 2 ( least brief ( &lt; 24 hr ) episodes ischemia manage nonsurgically without permanent deficit ) No history cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) subarachnoid hemorrhage within past 6 month Not pregnant nursing Fertile patient must use effective contraception ≥ 6 month completion bevacizumab therapy No neuropathy ( sensory motor ) &gt; grade 1 No active infection require antibiotic No circumstance would preclude study participation No known hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibodies No history allergic reaction polysorbate 80 ( e.g. , etoposide , vitamin E ) No invasive malignancy within past 5 year except nonmelanoma skin cancer localize breast cancer No serious , nonhealing wound , ulcer , bone fracture No significant traumatic injury within 28 day prior bevacizumab therapy No prior history abdominal fistula gastrointestinal perforation within past 36 month Granulating incision heal secondary intention evidence fascial dehiscence infection allow require weekly wound examinations No clinical symptom sign gastrointestinal obstruction require parenteral hydration and/or nutrition At least 28 day since intraabdominal abscess recover At least 3 year since prior adjuvant chemotherapy localize breast cancer Patients must remain free recurrent metastatic disease At least 3 year since prior radiotherapy localize cancer breast , head neck , skin Patient must remain free recurrent metastatic disease No prior radiotherapy portion abdominal cavity pelvis No concurrent amifostine protective agent No concurrent major surgical procedure open biopsy within 28 day prior bevacizumab therapy No core biopsy within 7 day prior bevacizumab therapy No prior therapy malignancy No prior cancer treatment contraindicates study therapy No prior antiVEGF drug , include bevacizumab</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>